Polyol biomarkers for congenital disorders of glycosylation
AssigneeMayo Foundation for Medical Education and Research
InventorsEva Morava-Kozicz, Tamas Kozicz, Devin Oglesbee, Kimiyo M. Raymond
Life of this patent
Estimating the term…
Abstract
Methods and materials for assessing the severity of congenital disorders of glycosylation (CDG), as well as methods and materials for treating CDG patients based on the assessment of CDG severity.
Claims23
1-8. (canceled)
A method for treating a mammal identified as (a) having a CDG and (b) having a biological sample containing an elevated level of one or more polyols, relative to the level of said one or more polyols in a biological sample from a control mammal not having said CDG,
- wherein said method comprises administering to said mammal a dose of an aldose reductase inhibitor (ARI) that is increased as compared to a dose of said ARI that would be administered to a mammal identified as having said CDG and as having a biological sample that does not contain an elevated level of said one or more polyols, relative to the level of said one or more polyols in said biological sample from said control mammal.
(canceled)
A method for treating a mammal identified as having a CDG, the method comprising:
- (a) measuring a level of one or more polyols in a biological sample from said mammal, and determining that a measured level of at least one of said one or more polyols is elevated relative to a level of the one or more polyols in a biological sample from a control mammal that does not have said CDG, and
- (b) administering to said mammal a dose of an ARI that is increased as compared to a dose of said ARI that would be administered to a mammal identified as having said CDG and as having a biological sample that does not contain an elevated level of said one or more polyols, relative to the level of said one or more polyols in said biological sample from said control mammal.
(canceled)
Dependencies are inferred from the claim text.